Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction System

Treace estimates the system represents a $300M expansion of its total addressable market.

Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI) completed the first surgical cases using its Tailorplasty MIS Tailor’s Bunion Correction System.

The system extends Treace’s instrument-guided correction platform to tailor’s bunions, also called bunionettes, which are deformities of the fifth metatarsal bone. It uses an incision of less than 1 cm and a fixation implant inserted over a guidewire. Treace anticipates commercialization in the first quarter of 2027, expanding its portfolio beyond its existing bunion correction systems.

Positive

• Minor pointFirst Tailorplasty surgical cases completed, extending Treace’s instrumented correction platform to tailor’s bunions.
• Minor point. Forward-looking: it has not happened yet and may not happen.Commercialization anticipated in the first quarter of 2027 would add Tailorplasty to Treace’s commercial portfolio.

Negative

• None.

News Explained

Treace estimates tailor’s bunions affect 5–10% of U.S. adults and describes Tailorplasty as a $300 million total-addressable-market expansion opportunity.

Key Figures

Estimated affected adult population: 5–10% Incision size: <1 cm TAM expansion opportunity: $300M +1 more

Estimated affected adult population

5–10%

Bunionettes

Incision size

<1 cm

Tailorplasty MIS procedure

TAM expansion opportunity

$300M

Company-estimated opportunity

Anticipated commercialization

First quarter of 2027

Tailorplasty System

Historical Context

1 past event · Latest: Sep 15

1 event

1. Sep 15

   Product showcase

   24h Move

   -0.4%

   Tailorplasty was listed among minimally invasive product innovations before the first surgical cases.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

metatarsal, guidewire, osteotomy, tam

4 terms

metatarsal medical

"painful deformities of the fifth metatarsal"

One of the long bones in the middle part of the foot that connect the ankle bones (tarsals) to the toe bones (phalanges); each foot normally has five metatarsals numbered first through fifth from the inside (big toe side) to the outside. They bear and transfer weight when standing and walking and are common sites for stress fractures and traumatic breaks because they bridge the moving front of the foot and the more rigid hindfoot.

guidewire technical

"inserts over a guidewire for controlled, reproducible correction"

A guidewire is a thin, flexible metal wire used by doctors to steer catheters and other tools through blood vessels or body passages during minimally invasive medical procedures. For investors, guidewires matter because they are essential, often single-use components whose sales track procedure volume, hospital buying patterns, regulatory approvals, patent protection and liability exposure—similar to a small but critical part in a machine that drives steady, repeatable revenue for device makers.

osteotomy medical

"proper alignment of the osteotomy, and secure fixation"

Osteotomy is a surgical procedure that cuts and repositions bone to correct alignment, relieve pressure, or reshape a joint—think of adjusting a bent frame so parts fit and work together again. For investors, it matters because the frequency and success of these operations drive demand for orthopedic implants, surgical tools, rehabilitation services and related reimbursement; changes in procedure rates, outcomes or technology adoption can directly affect revenue and regulatory risk for medical-device and health-care companies.

tam financial

"an underserved $300M TAM expansion opportunity"

Total addressable market (TAM) is an estimate of the total revenue opportunity available for a product or service if it captured every possible customer. Think of it as the size of the whole pie a business could potentially eat from; investors use it to judge how large a company could grow, whether current sales are a small slice or a meaningful portion, and to compare growth opportunities across industries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures

PONTE VEDRA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, today announced the successful completion of the first cases utilizing its Tailorplasty™ MIS Tailor’s Bunion Correction System.

The Tailorplasty™ procedure extends Treace's instrumented bunion correction platform to tailor's bunions, or "bunionettes” which are painful deformities of the fifth metatarsal estimated to affect approximately 5-10% of the adult population.

Tailorplasty™ provides instrument-guided surgical correction of the bunionette deformity through a MIS (<1cm incision) and features a unique fixation implant that inserts over a guidewire for controlled, reproducible correction and stability during healing.

Surgeon design team member for the Tailorplasty™ System, Jonathan Kaplan, MD (Prisma Health / University of South Carolina School of Medicine), commented, “Tailor's bunions are a condition I commonly treat in my practice, both in my bunion patients and as standalone deformities. Tailor’s bunion correction has traditionally required either a large open incision or a challenging freehand MIS technique, where achieving proper alignment of the osteotomy, and secure fixation, can be unpredictable and lead to inconsistent results.  Our goal with the Tailorplasty™ System was to help surgeons confidently achieve a quick, controlled, and accurate correction of this deformity through a MIS approach and help patients return to their active lives quickly.”

“Our initial Tailorplasty™ cases mark another important step in the continued expansion of our market-leading 3D bunion correction portfolio,” said John T. Treace, CEO and Chairman of Treace. “As a common deformity affecting an estimated 5-10% of adults in the US, we estimate the Tailorplasty™ System represents an underserved $300M TAM expansion opportunity for our business. Consistent with our other best-in-class bunion systems, Tailorplasty™ delivers a new solution aimed to transform a challenging freehand surgery to one with instrumented control and reproducibility. The addition of the Tailorplasty™ System further advances Treace’s objective to become a more comprehensive foot and ankle technology partner for our surgeon customers.”

Commercialization of the Tailorplasty™ System is anticipated in the first quarter of 2027. To learn more, click here.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: anticipated future product launches and the timing of such product launches, including the anticipated commercialization of the Tailorplasty™ System; estimates of the number of tailor’s bunion procedures and the size of the addressable market, including the potential for market expansion; and expectations regarding increased procedural utilization, deepening surgeon engagement, and increased addressable market. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026, and Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date, and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^®3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty^® 3D Minimally Invasive Bunion Correction System and the Percuplasty^® Percutaneous 3D Bunion Correction System, and the SpeedMTP^® 1^st MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate^® rapid compression implant platform to new applications, providing surgeons with advanced digital solutions with its IntelliGuide^® patient specific, pre-op planning and cut guide technology, and offering SuperBite™ Fully-Threaded Compression Screws for use in fusions and osteotomies throughout the foot. For more information, please visit www.treace.com.

Dr. Jonathan Kaplan is a paid consultant of the Company.

To learn more about Treace, connect with us on LinkedIn, X, Facebook, and Instagram.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0283d751-19be-4242-8d69-83f463851312

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Treace expect to commercialize the Tailorplasty system?

Treace anticipates commercializing the Tailorplasty system in the first quarter of 2027. The first surgical cases using the system have been completed.